Phase I MM-005 Dose-Escalation Trial of Pomalidomide, Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma


Phase I MM-005 Dose-Escalation Trial of Pomalidomide, Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Kenneth C Anderson, MD (3/29/13)

Richardson PG et al. MM-005: A Phase 1, multicenter, open-label, dose-escalation study to determine the maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-dose dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Proc ASH 2012;Abstract 727.

Dr Anderson is Kraft Family Professor of Medicine at Harvard Medical School, Director of the Jerome Lipper Multiple Myeloma Center and Director of the LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute in Boston, Massachusetts.